Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Biochem Pharmacol. 2017 Mar 4;135:22–34. doi: 10.1016/j.bcp.2017.02.021

Figure 2. The effect of dietary administration of ASA, CUR, and their combination in AOM/DSS-induced CAC. (A).

Figure 2

The suppression of the DAI by 0.02% ASA, 2% CUR, and 0.01% ASA+1% CUR. (B) The effect of ASA, CUR, and their low-dose combination on tumor incidence in AOM/DSS-induced CAC. The tumor incidence (%) of each group was calculated from the number of mice with tumor growth over the number of mice examined. (C) The effect of ASA and CUR, alone or in combination, in decreasing tumor multiplicity in AOM/DSS-induced CAC. Tumor multiplicity was calculated from the total number of tumors in each group divided by the number of mice in each group. (D–I) Histological observation of the control group (D), the model group with AOM/DSS administration (E, F), mice treated with 0.02% ASA (G), mice treated with 2% CUR (H), and mice treated with 0.01% ASA+1% CUR (I). * P < 0.05 versus the model group.